Literature DB >> 8341136

The adenosine kinase inhibitor, 5-iodotubercidin, is not protective against cerebral ischemic injury in the gerbil.

J W Phillis1, M Smith-Barbour.   

Abstract

5-Iodotubercidin is a potent inhibitor of the enzyme adenosine kinase. It has a recognized ability to enhance interstitial fluid levels of the cerebroprotective purine, adenosine, in the hypoxic brain, and an anticonvulsant action, which is thought to be a consequence of its ability to increase extracellular adenosine levels. 5-Iodotubercidin (1 mg/kg, i.p.) was therefore tested for its ability to reduce cerebral ischemic injury in a gerbil model. Unanesthetized gerbils were subjected to a 5 min period of bilateral carotid artery occlusion and then maintained in an environmental chamber at 30 degrees C for 5 hr to counteract the hypothermia-inducing action of 5-iodotubercidin. As estimated from the extent of the increases in locomotor activity and the magnitude of hippocampal CAI layer pyramidal cell loss, 5-iodotubercidin (1 mg/kg) failed to have a cerebroprotective effect against ischemic injury.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341136     DOI: 10.1016/0024-3205(93)90701-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Profound hypothermia after adenosine kinase inhibition in A1AR-deficient mice suggests a receptor-independent effect of intracellular adenosine.

Authors:  Christoph Eisner; SooMi Kim; Alexandra Grill; Yan Qin; Marion Hoerl; Josephine Briggs; Hayo Castrop; Manfred Thiel; Jurgen Schnermann
Journal:  Pflugers Arch       Date:  2016-12-14       Impact factor: 3.657

2.  Modulation of bladder function by luminal adenosine turnover and A1 receptor activation.

Authors:  H Sandeep Prakasam; Heather Herrington; James R Roppolo; Edwin K Jackson; Gerard Apodaca
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-02

Review 3.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.